Position
Forefront Analytics, LLC in CytomX Therapeutics, Inc.
Back to the book · All holders of CTMX
Estimated mark uses implied 13F prices (value ÷ shares). Adds are treated as happening at this quarter’s mark; cuts at last quarter’s. Share jumps can be splits, not buys. This is not realized P&L.
Latest estimated mark $5.49K$4.26 → $4.70
| Quarter | Shares | Value | Implied px | Est. mark | Flow | Weight |
|---|---|---|---|---|---|---|
| Q4 2025 | 18.7K | $79.7K | — | — | — | 0.1% |
| Q1 2026 | 12.5K | $58.6K | $4.70 | $5.49K | −$26.5K | 0.1% |